Navigation Links
Actinium Pharmaceuticals To Present At The LD Micro Conference
Date:11/21/2013

NEW YORK, Nov. 21, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB) ("Actinium" or "the Company"), a biopharmaceutical Company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, announced today that Dr. Kaushik J. Dave, President and CEO, will present at the 6th Annual LD Micro Conference in Los Angeles from December 3rd through 5th, 2013. Dr. Dave will present a corporate update on Thursday, December 5, 2013 at 12:30 pm Pacific.

Presentation Information:

Date:              Thursday, December 5, 2013
Time:              12:30 pm Pacific
Location:         Luxe Sunset Bel Air Hotel - Track #4, Los Angeles, CA
Webcast:        http://wsw.com/webcast/ldmicro5/ATNM
1x1 Meetings Contact: Corey Sohmer (646) 459-4201

A live webcast of the presentation will be available via the "Investor Relations" page of the Actinium website, www.actiniumpharmaceuticals.com. A replay of the webcast will also be archived on Actinium's website for 90 days following the presentation.

LD Micro Conference:

The LD Micro Conference is a three-day conference organized by LD Micro, an internet-based newsletter that provides self-directed investors information on selected public companies that in the opinion of LD Micro have great investment potential. More than two hundred institutions focused on small and micro-cap stocks are expected to attend.  A record 580 people attended the 2012 event. For more information, please visit the conference website at http://www.ldmicro.com/

About Actinium Pharmaceuticals

Actinium Pharmaceuticals, Inc. (OTCQB: ATNM.OB), is a New York based biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers.  Actinium's targeted radiotherapy is based on its proprietary delivery platform for the therapeutic utilization of alpha emitting actinium-225 and bismuth-213 radiopharmaceuticals in conjunction with monoclonal antibodies.  The Company also develops other radiopharmaceuticals for select applications.

For more information:

Visit our web site www.actiniumpharmaceuticals.com

Contacts:

Media:
Dennis S. Dobson Jr.
Tel: (203) 258-0159
Email: dennisdobsonjr@dobsonmediagroup.com  

Actinium Pharmaceuticals, Inc.
Investor/Media Relations: Corey Sohmer, (646) 459-4201
Email: csohmer@actiniumpharmaceuticals.com

Forward-Looking Statement for Actinium Pharmaceuticals, Inc.

This news release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, or financial performance. No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Actinium Pharmaceuticals undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


'/>"/>
SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actinium Pharmaceuticals Appoints Richard Steinhart As New Independent Director
2. Actinium Pharmaceuticals to Host Corporate Update and Virtual Roadshow Conference Call on November 11
3. Actinium Pharmaceuticals Appoints Corey Sohmer As Vice President Of Finance And Business Development
4. Actinium Pharmaceuticals Appoints Kaushik J. Dave, Ph.D., MBA As President, Chief Executive Officer And Director
5. Actinium Pharmaceuticals Clinical Results Featured at a United Nations Forum
6. Actinium Pharmaceuticals, Inc. Receives $3.5m from Exercise of Warrants
7. Actinium Pharmaceuticals Clinical Results to be Presented at 8th International Symposium on Targeted Alpha Therapy Conference
8. Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application
9. Cactus Ventures, Inc. Changes Name to Actinium Pharmaceuticals, Inc.
10. Actinium Pharmaceuticals, Inc. To Present at the 15th Annual BIO CEO Investor Conference
11. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... , Jan. 18, 2017 The Global ... understanding and access to partnering deals and agreements entered ... Trends in partnering deals - Top deals by value ... of development, technology type The report provides understanding ... into by the world,s leading healthcare companies. The ...
(Date:1/19/2017)... , Jan. 18, 2017 The Academy ... and Drug Administration (FDA) for its release today ... population health decision makers can proactively share clinical ... as well as emerging therapies awaiting FDA approval. ... consensus recommendations that AMCP developed during two multi-stakeholder ...
(Date:1/18/2017)... PORTLAND, Oregon and PUNE, India ... report published by Allied Market Research, titled, "Breast Imaging Technologies ... projects that the global breast imaging technologies market size was ... reach $4,502 million by 2022, growing at a CAGR of ... and Europe together accounted for ...
Breaking Medicine Technology:
(Date:1/19/2017)... TX (PRWEB) , ... January 19, 2017 , ... Attorney ... for the fifth consecutive year donated money to the Triumph Over Kid Cancer foundation. ... Ragan was one of those children. James saw firsthand the effect of the critical ...
(Date:1/19/2017)... ... ... The CHP suggests that California drivers can avoid hydroplaning as well as ... the space between themselves and other vehicles, according to a January 3 article ... notes that, rain or shine, drivers should always incorporate safe driving practices in their ...
(Date:1/19/2017)... ... January 19, 2017 , ... The 21st Century Cures Act’s Impact ... Webinar**, Jan. 26, 2016 — 1:30 p.m. – 3:00 p.m. ET, http://www.fdanews.com/21stcenturycures          ... Act in order to thrive this year? , The passage of the act means ...
(Date:1/19/2017)... (PRWEB) , ... January 19, 2017 , ... Infinity® Massage ... business plan and implement new sales and marketing strategies. Grover comes with a total ... last 5 and a half years as Executive Vice President of Direct Sales at ...
(Date:1/19/2017)... ... January 19, 2017 , ... Fillers are known for building ... know that popular cosmetic fillers can enhance earlobes and rejuvenate an ... of the MilfordMD Cosmetic Dermatology Surgery & Laser Center, in Milford, Penn. “People ...
Breaking Medicine News(10 mins):